KUALA LUMPUR, Dec 7 — Adagene Inc (Adagene) has announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from Dec 8 to 11.

In the first presentation of results from an ongoing dose-escalation trial of monotherapy in patients with advanced metastatic tumours, ADG116 demonstrated a strong safety profile and early signals of efficacy, including dose-dependent T-cell activation and tumour suppression in treatment-resistant ‘cold’ and ‘warm’ tumours such as pancreatic, ovarian and renal cell cancers.

On the findings, Dr Gary Richardson, OAM, MBBS, FRACP, Group Director at Cabrini Health Research, Director at Szalmuk Family Department of Medical Oncology and Professor of Medicine at Monash University, Australia said in a statement:

“These encouraging clinical data demonstrate the promising safety profile of ADG116 monotherapy in patients with advanced solid tumours across 15 different tumour types, the majority of which are resistant to standard therapy.

The most exciting thing about these results is that we have also seen the early signals of efficacy in ‘cold’ tumors such as pancreatic and certain gynecological cancers, which do not respond to current immunotherapies.

“We want to see this type of unique activity, which suggests that this treatment may look different and potentially better than the options we have available today.”

Source: BERNAMA News Agency